Par Health USA recalled 22 lots of Argatroban injection nationwide after visible particulate matter turned up in vials of the blood thinner used in hospitals during percutaneous coronary intervention and other procedures that need rapid anticoagulation.
What regulators say about risk
The Food and Drug Administration published the recall notice Oct. 14. Par Health said particles were identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel. Injecting contaminated argatroban carries a reasonable probability of serious harm, including pulmonary emboli, blood-vessel blockages, tissue damage, and vein inflammation that can promote clotting—the opposite of the drug’s purpose.
The company reported no adverse events tied to the recall as of the announcement date. That does not mean complications will stay at zero; hospitals are being told to quarantine affected stock immediately.
Who is affected
Argatroban is a hospital drug, not a take-home prescription for most patients. Lots went to wholesalers and hospital pharmacies between late 2024 and spring 2026. If you underwent a cardiac catheterization or similar procedure during that window, your risk depends on whether the facility used recalled inventory—a detail only the hospital pharmacy can confirm.
Patients should not stop any prescribed anticoagulant on their own. If you develop unexpected shortness of breath, chest pain, or leg swelling after a recent procedure, seek emergency care and tell clinicians about your infusion history.
What hospitals must do
Par Health said it notified wholesale and hospital accounts with written instructions to stop distribution and return product. Facilities that forwarded vials must alert downstream recipients. Pharmacy directors typically compare internal lot logs against FDA lot lists posted with the recall letter.
The recall follows other 2026 particulate-matter notices from the same manufacturer family, including a Brevital Sodium recall earlier in October. FDA inspectors have been focused on injectable contamination after a string of glass and stopper-related findings across the sterile injectables sector.
Broader supply-chain read
Argatroban is a niche but critical agent when heparin-induced thrombocytopenia rules out standard heparin therapy. Shortages from quarantined lots can force hospitals to substitute alternative anticoagulants with different monitoring requirements.
Elective procedure schedulers may see brief delays if cath labs pause while pharmacies verify inventory. That is preferable to administering a vial with metal or plastic fragments suspended in solution.
How to check a lot
The FDA notice includes product codes and lot numbers. Hospital patients rarely see vial labels, but you can ask the facility’s patient advocate office whether your visit occurred while recalled stock was on the shelf. Keep discharge paperwork that lists infused medications; it speeds pharmacy lookups.